文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

常规TNFα抑制剂治疗失败的难治性非感染性慢性前葡萄膜炎儿童的替代生物制剂治疗

Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis.
PubMed 文献 · Am J Ophthalmol · 2022-07-19

回顾性非随机临床研究纳入52例非感染性慢性前葡萄膜炎(CAU)儿童,比较甲氨蝶呤(MTX)单药、常规TNFα抑制剂(cTNFi)与替代生物制剂(ABT)治疗。ABT组(9例)治疗前人均眼部并发症总数高于MTX组和cTNFi组,9例ABT治疗后CAU均获控制且无新发眼部并发症。

要点

  • 52例CAU儿童中75%合并幼年特发性关节炎。
  • ABT组治疗前人均眼部并发症3.4个,高于MTX组0.7个(P<.001)和cTNFi组1.5个(P<.001)。
  • 9例ABT治疗后CAU均获控制,局部糖皮质激素减至≤2滴/天且无新发眼部并发症。

核心结论

  • 阿巴西普、戈利木单抗和托珠单抗等替代生物制剂对MTX和cTNFi治疗失败的CAU儿童有用。
  • ABT治疗获控制的患者较常规治疗者在ABT前有更多疾病活动、眼部并发症和抗cTNFi中和抗体。
  • 需要更大规模研究证实这些发现。

研究设计与样本

  • 回顾性、非随机临床研究,设置于三级中心。
  • 研究人群为52例非感染性CAU儿童。
  • 比较接受MTX单药、cTNFi和ABT治疗超过3个月患者的临床特征、葡萄膜炎病程、并发症和治疗。
  • 主要结局指标为ABT(阿巴西普、托珠单抗和/或戈利木单抗)在常规治疗失败儿童中的成功率。

主要发现

  • 52例CAU儿童中75%合并幼年特发性关节炎。
  • CAU获控制者:MTX单药组15例,cTNFi组28例,ABT组9例(阿巴西普1例、托珠单抗3例、戈利木单抗5例)。
  • ABT组ABT前人均眼部并发症总数高于MTX组(3.4 vs 0.7,P<.001)和cTNFi组(3.4 vs 1.5,P<.001)。
  • 全部9例ABT治疗均使CAU获控制,局部糖皮质激素减至≤2滴/天,无新发眼部并发症。

关键数值与推荐

  • CAU获控制者:MTX单药组15例、cTNFi组28例、ABT组9例。
  • ABT组ABT前人均眼部并发症总数3.4个,MTX组0.7个(P<.001),cTNFi组1.5个(P<.001)。
  • ABT组9例治疗后局部糖皮质激素减至≤2滴/天,无新发眼部并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要更大规模研究证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A significant number of children with noninfectious, chronic anterior uveitis (CAU) fail to respond to conventional therapy; however, successful alternative biologic treatments (ABT) have not been well described. This study aims to review the clinical and treatment characteristics of children with CAU who require ABT. DESIGN: Retrospective, nonrandomized clinical study. METHODS: Setting: Tertiary center. STUDY POPULATION: Children with noninfectious CAU. OBSERVATION PROCEDURES: Clinical characteristics, uveitis course, complications, and treatment were compared among patients treated with methotrexate (MTX) monotherapy, conventional TNFα inhibitors (cTNFi), and ABT for >3 months. MAIN OUTCOME MEASURE: Success of ABT (abatacept, tocilizumab, and/or golimumab) in children failing conventional treatment. RESULTS: Of the 52 children with CAU, 75% had juvenile idiopathic arthritis. CAU was controlled in 15 children receiving MTX monotherapy, 28 receiving cTNFi, and 9 receiving ABT (n = 1, abatacept; n = 3, tocilizumab; n = 5, golimumab). Patients in the ABT group had a greater number of total ocular complications per person before ABT than those in the control groups (3.4 vs 0.7 [MTX], P < .001, and 1.5 [cTNFi], P < .001, respectively). In all 9 children on ABT, treatment led to control of CAU and topical glucocorticoids tapered to ≤2 drops/d with no new ocular complications. CONCLUSIONS: In this study, alternative biologics (abatacept, golimumab, and tocilizumab) were useful for treating CAU in children who fail MTX and cTNFi therapy. Patients who were controlled on ABT had more disease activity, ocular complications, and anti-cTNFi neutralizing antibodies (before ABT) than those managed with conventional therapy. Larger studies are required to confirm these findings.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Miraldi Utz V, Angeles-Han ST, Mwase N, et al. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. Am J Ophthalmol. 2022. PMID: 35863492. doi:10.1016/j.ajo.2022.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。